Stay updated with breaking news from Randy Longman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Weill Cornell researchers find inflammatory bowel disease drug works by modulating the activity of a group of gut bacteria that are more abundant in patients who respond to the drug.
Although it is one of the oldest medications used to treat patients with inflammatory bowel disease (IBD) and an effective treatment for an associated arthritis condition called spondyloarthritis (SpA), sulfasalazine's mechanism of action has been unclear.
Dr. Iliyan D. Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology, co-director of the Microbiome Core and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease (IBD) at Weill Cornell Medicine, is the lead investigator on a grant to Weill Cornell Medicine from The Leona M. and Harry B. Helmsley Charitable Trust to target pathogenic fungi in patients with Crohn's disease.
The findings of a recent study headed by Weill Cornell Medicine and NewYork-Presbyterian researchers, suggests that changes in a single gene allow dangerous gut bacteria to trigger the inflammation that underlies Crohn's disease.
According to a recent study headed by Weill Cornell Medicine and NewYork-Presbyterian researchers, changes in a single gene allow dangerous gut bacteria to trigger the inflammation that underlies Crohn's disease